Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057341 · ClinicalTrials.gov registry record · Phase 2
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02057341 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 12 participants.
The verdict
NCT02057341, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a Phase 2 pilot study, involving a 48-week treatment period, designed to test the effectiveness of investigational study drug ARRY-371797 in treating patients with symptomatic genetic dilated cardiomyopathy due to a lamin A/C gene mutation, and to further evaluate the drug's safety. Approximately 12 patients from the US will be enrolled in this study.
Interventions
- DRUG ARRY-371797, p38 inhibitor; oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02057341
The ClinicalTrials.gov registry entry for NCT02057341 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARRY-371797, p38 inhibitor; oral is the first listed.
NCT02057341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02057341 about?
NCT02057341 is a clinical study titled "A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy". This is a Phase 2 pilot study, involving a 48-week treatment period, designed to test the effectiveness of investigational study drug ARRY-371797 in treating patients with symptomatic genetic dilated cardiomyopathy due to a lamin A/C gene mutation, and to further evaluate the drug's safety. Approxim...
What is the current status of trial NCT02057341?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2014-02. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02057341?
The interventions under investigation include: ARRY-371797, p38 inhibitor; oral (DRUG).
Who is sponsoring clinical trial NCT02057341?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.